First National Bank of Omaha’s United Therapeutics UTHR Stock Holding History

First National Bank of Omaha’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.82M	Sell	5,198 -540	-9%	-$304K	0.08%	220
2026 Q1	$3.4M	Sell	5,738 -159	-3%	-$79.2K	0.11%	200
2025 Q4	$2.87M	Sell	5,897 -2,314	-28%	-$1.08M	0.09%	220
2025 Q3	$3.44M	Sell	8,211 -380	-4%	-$128K	0.22%	123
2025 Q2	$2.47M	Buy	8,591 +239	+3%	+$71.4K	0.16%	168
2025 Q1	$2.57M	Buy	8,352 +2,872	+52%	+$984K	0.18%	154
2024 Q4	$1.93M	Sell	5,480 -245	-4%	-$90.1K	0.13%	187
2024 Q3	$2.05M	Sell	5,725 -206	-3%	-$69.6K	0.13%	189
2024 Q2	$1.89M	Sell	5,931 -2,421	-29%	-$641K	0.12%	185
2024 Q1	$2.57M	Buy	+8,352	New	+$1.88M	0.18%	154
2018 Q4	–	Sell	-31,991	Closed	-$4.41M	–	366
2018 Q3	$4.41M	Hold	31,991	–	–	0.25%	131
2018 Q2	$4.41M	Hold	31,991	–	–	0.26%	126
2018 Q1	$4.41M	Hold	31,991	–	–	0.26%	124
2017 Q4	$4.41M	Hold	31,991	–	–	0.26%	125
2017 Q3	$4.41M	Hold	31,991	–	–	0.27%	119
2017 Q2	$4.41M	Hold	31,991	–	–	0.28%	118
2017 Q1	$4.41M	Hold	31,991	–	–	0.27%	119
2016 Q4	$4.41M	Buy	+31,991	New	+$4.08M	0.28%	112
2016 Q1	–	Sell	-1,985	Closed	-$311	–	350
2015 Q4	$311	Sell	1,985 -410	-17%	-$59.7K	0.02%	302
2015 Q3	$314	Sell	2,395 -2,118	-47%	-$340K	0.02%	302
2015 Q2	$721	Hold	4,513	–	–	0.05%	229
2015 Q1	$721	Sell	4,513 -1,262	-22%	-$192K	0.05%	229
2014 Q4	$748K	Sell	5,775 -990	-15%	-$128K	0.05%	236
2014 Q3	$870K	Sell	6,765 -110	-2%	-$11.3K	0.06%	221
2014 Q2	$608K	Hold	6,875	–	–	0.04%	269
2014 Q1	$647K	Sell	6,875 -100	-1%	-$10.2K	0.05%	260
2013 Q4	$788K	Buy	6,975 +225	+3%	+$20.3K	0.06%	222
2013 Q3	$533K	Buy	6,750 +800	+13%	+$58.5K	0.05%	266
2013 Q2	$391	Buy	+5,950	New	+$383K	0.03%	304

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

First National Bank of Omaha's UTHR Position: Q2 2026 in Review

First National Bank of Omaha reduced its United Therapeutics (UTHR) stake by 9.4% in Q2 2026, selling an estimated $304K and leaving 5,198 shares worth $2.82M. The position accounts for 0.08% of the portfolio, ranked #220.

First National Bank of Omaha first reported a position in UTHR in Q2 2013 and has held it in 29 quarters since. The position peaked at $4.41M in Q3 2018. 417 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

First National Bank of Omaha held 5,198 shares of United Therapeutics worth $2.82M as of Q2 2026.
First National Bank of Omaha sold 540 United Therapeutics shares in Q2 2026, an estimated $304K.
United Therapeutics made up 0.08% of First National Bank of Omaha's portfolio in Q2 2026, its #220 holding.
First National Bank of Omaha first reported a position in United Therapeutics in Q2 2013 and has held it in 29 quarters since.
First National Bank of Omaha's United Therapeutics position peaked at $4.41M in Q3 2018.
417 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on First National Bank of Omaha's 13F filing for Q2 2026, filed 7 Aug 2026.